Victory Capital Management Inc Kinnate Biopharma Inc. Transaction History

Victory Capital Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	SELL	$5.26 - $12.19 $234,227 - $542,820	-44,530 Reduced 38.54%	71,020 $433,000
Q3 2022 Nov 02, 2022	SELL	$9.86 - $15.76 $29,382 - $46,964	-2,980 Reduced 2.51%	115,550 $1.38 Million
Q2 2022 Aug 01, 2022	BUY	$7.43 - $13.0 $241,400 - $422,370	32,490 Added 37.76%	118,530 $1.5 Million
Q1 2022 May 04, 2022	SELL	$7.73 - $17.99 $232,673 - $541,499	-30,100 Reduced 25.92%	86,040 $969,000
Q4 2021 Feb 07, 2022	BUY	$16.5 - $25.48 $344,355 - $531,767	20,870 Added 21.91%	116,140 $2.06 Million
Q3 2021 Nov 02, 2021	SELL	$17.81 - $24.87 $13,713 - $19,149	-770 Reduced 0.8%	95,270 $2.19 Million
Q2 2021 Aug 03, 2021	SELL	$22.19 - $31.55 $141,350 - $200,973	-6,370 Reduced 6.22%	96,040 $2.24 Million
Q1 2021 May 04, 2021	SELL	$26.99 - $40.0 $117,136 - $173,600	-4,340 Reduced 4.07%	102,410 $3.19 Million
Q4 2020 Feb 01, 2021	BUY	$36.35 - $45.25 $3.88 Million - $4.83 Million	106,750 New	106,750 $4.25 Million

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Victory Capital Management Inc with notifications on news.